

## Supporting Information

© Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2014

### **Improved Bioactivity of Antimicrobial Peptides by Addition of Amino-Terminal Copper and Nickel (ATCUN) Binding Motifs**


M. Daben Libardo,<sup>[a]</sup> Jorge L. Cervantes,<sup>[b]</sup> Juan C. Salazar,<sup>[b]</sup> and Alfredo M. Angeles-Boza<sup>\*[a]</sup>

cmdc\_201402033\_sm\_miscellaneous\_information.pdf  
cmdc\_201402033\_sm\_movie.avi


<b><u>Table of contents</u></b>	<b>Page #</b>
<b>Figure S1.</b> Rates of ascorbic acid consumption in the (A) presence and (B) absence of the H <sub>2</sub> O <sub>2</sub>	S-3
<b>Table S1.</b> Minimum Inhibitory Concentration of ATCUN-AMPs with and without the addition of 32 μM Cu <sup>2+</sup> .	S-4
<b>Table S2.</b> Summary of characterization data for synthetic tripeptides.	S-5
<b>Table S3.</b> Summary of characterization data of ATCUN-AMPs.	S-6

## EXPERIMENTAL DETAILS

(A)



(B)



**Figure S1.** Rates of ascorbic acid consumption in the (A) presence and (B) absence of the H<sub>2</sub>O<sub>2</sub>. Reduced ascorbic acid reacts with reactive oxygen species generated by the Cu<sup>II</sup>-ATCUN complexes.

**Table S1.** Minimum Inhibitory Concentration of ATCUN-AMPs with and without the addition of 32  $\mu\text{M}$  Cu<sup>2+</sup>.

Peptide	<i>B. subtilis</i>		<i>E. coli</i>	
	w/o Cu <sup>2+</sup>	w/ 32 $\mu\text{M}$ Cu <sup>2+</sup>	w/o Cu <sup>2+</sup>	w/ 32 $\mu\text{M}$ Cu <sup>2+</sup>
Anoplín	4	4	16	16
DAH-Anoplín	2	2	8	8
GGH-Anoplín	2	2	4	4
VIH-Anoplín	0.5	0.5	2	2
PAP	0.5	0.25	1	1
DAH-PAP	0.25	0.5	0.25	0.25
GGH-PAP	0.125	0.06	0.125	0.06
VIH-PAP	0.125	0.03	0.25	0.125
<i>sh</i> -Buforín	8	8	32	16
<i>sh</i> -DAH-Buforín	2	2	16	16
<i>sh</i> -GGH-Buforín	4	4	16	8
<i>sh</i> -VIH-Buforín	2	1	8	4

**Table S2.** Summary of characterization data for synthetic tripeptides. Purity was established by reinjecting purified peptides on a C<sub>18</sub> analytical column using 0.1% TFA in H<sub>2</sub>O (Buffer A) and 0.1% TFA in ACN (Buffer B) with a linear gradient of 0-95% Buffer B over 25 mins. Identities were confirmed using ESI-MS.

Tripeptide	Retention Time (mins)	% Purity	Molecular Weight	Observed [M+H] <sup>+</sup>
DAH-NH <sub>2</sub>	6.124	98.05	340.68	341.1
DMH-NH <sub>2</sub>	6.090	96.93	400.46	401.1
DSH-NH <sub>2</sub>	5.917	95.28	356.34	357.1
DTH-NH <sub>2</sub>	6.123	96.94	370.37	371.1
EAH-NH <sub>2</sub>	5.975	97.82	354.34	355.1
GGH-NH <sub>2</sub>	6.090	98.05	268.27	269.1
GKH-NH <sub>2</sub>	6.029	96.89	339.30	340.2
GNH-NH <sub>2</sub>	5.935	95.29	325.32	326.1
LKH-NH <sub>2</sub>	6.579	98.11	395.50	396.2
NGH-NH <sub>2</sub>	5.931	97.87	325.32	326.1
RTH-NH <sub>2</sub>	6.065	98.36	411.47	412.2
SMH-NH <sub>2</sub>	6.091	96.29	372.45	373.1
VIH-NH <sub>2</sub>	6.069	97.72	366.46	367.2

**Table S3.** Summary of characterization data of ATCUN-AMPs. Purity was established by reinjecting purified peptides on a C<sub>18</sub> analytical column using 0.1% TFA in H<sub>2</sub>O (Buffer A) and 0.1% TFA in ACN (Buffer B) with a linear gradient of 30-60% Buffer B over 30 mins. Identities were confirmed by ESI-MS. MS ion peaks in normal type are calculated whereas the ones in bold type are observed.

Peptide	Retention Time (mins)	% Purity	Molecular Weight	[M+2H] <sup>+</sup>	[M+3H] <sup>+</sup>	[M+4H] <sup>+</sup>
Anoplin	14.38	96.34	1153.51	577.75 <b>577.8</b>	-	-
DAH-Anoplin	12.85	98.93	1476.82	739.41 <b>739.0</b>	-	-
GGH-Anoplin	12.81	97.56	1404.75	703.37 <b>703.1</b>	-	-
VIH-Anoplin	14.14	98.97	1502.94	752.47 <b>752.0</b>	-	-
Buforin II	11.25	98.34	2433.87	-	812.29 <b>812.2</b>	609.47 <b>609.6</b>
DAH-Buforin II	11.12	98.38	2757.18	-	920.06 <b>919.9</b>	690.29 <b>690.4</b>
GGH-Buforin II	11.18	98.52	2685.12	-	896.04 <b>896.0</b>	672.28 <b>672.3</b>
VIH-Buforin II	11.27	99.47	2783.3	-	928.76 <b>928.7</b>	696.82 <b>696.9</b>
sh-Buforin II	11.41	99.33	2002.43	1002.21 <b>1002.1</b>	668.47 <b>668.4</b>	-
DAH-sh-Buforin II	11.32	98.64	2325.73	1163.86 <b>1163.5</b>	776.24 <b>775.9</b>	-
GGH-sh-Buforin II	11.31	99.36	2253.67	1127.83 <b>1127.7</b>	752.22 <b>751.8</b>	-
VIH-sh-	11.36	98.39	2351.86	1176.93	784.95	-

Buforin II				<b>1177.0</b>	<b>784.7</b>	
Indolicidin	16.06	99.51	1906.29	954.14 <b>953.6</b>	636.43 <b>636.3</b>	-
DAH- Indolicidin	15.34	99.67	2229.6	1115.8 <b>1115.0</b>	744.2 <b>744.4</b>	-
GGH- Indolicidin	14.35	98.52	2157.54	1079.77 <b>1079.7</b>	720.18 <b>719.9</b>	-
VIH- Indolicidin	16.38	98.60	2255.72	1128.86 <b>1128.1</b>	752.91 <b>752.7</b>	-
PAP	11.25	97.97	1523.01	762.50 <b>762.2</b>	508.67 <b>508.7</b>	-
DAH-PAP	11.63	98.30	1846.32	924.16 <b>924.4</b>	616.44 <b>616.4</b>	-
GGH-PAP	11.48	98.05	1774.25	888.12 <b>887.7</b>	592.42 <b>592.4</b>	-
VIH-PAP	11.72	97.69	1872.44	937.22 <b>936.9</b>	625.15 <b>625.1</b>	-
Triterpticin	14.89	99.34	1901.28	951.64 <b>951.1</b>	634.76 <b>634.7</b>	-
DAH- Triterpticin	14.59	99.23	2224.59	1113.291 <b>113.9</b>	742.53 <b>742.3</b>	-
GGH- Triterpticin	14.52	98.35	2152.52	1077.26 <b>1078.1</b>	718.51 <b>718.3</b>	-
VIH- Triterpticin	15.09	99.26	2250.71	1126.35 <b>1126.6</b>	751.23 <b>750.9</b>	-